Contents

Development of Vascular Disrupting Agents .................................................. 1
Graeme J. Dougherty and David J. Chaplin

Part I  Pre-Clinical Development

The Discovery and Characterisation of Tumour Endothelial Markers .................. 31
Dario Neri and Roy Bicknell

The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs) .................................................. 49
R. Barbara Pedley and Gillian M. Tozer

Combination Therapy with Chemotherapy and VDAs .................................. 77
Givlia Taraboletti, Katiuscia Bonezzi, and Raffaella Giavazzi

Lessons from Animal Imaging in Preclinical Models .................................... 95
Lesley D. McPhail and Simon P. Robinson

Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action ........................................ 117
Yuval Shaked, Paul Nathan, Laura G.M. Daenen, and Robert S. Kerbel

Part II  Imaging in the Development of Vascular Disruptive Agents

MRI to Assess Vascular Disruptive Agents ................................................. 137
Martin Zweifel and Anwar R. Padhani

Contrast Ultrasound in Imaging Tumor Angiogenesis .................................. 165
Grzegorz Korpanty and Rolf A. Brekken
Part III  Clinical Development

The Clinical Development of Tubulin Binding Vascular Disrupting Agents ................................................................. 183
Martin Zweifel and Gordon Rustin

ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy ................................................................. 217
Bruce C. Baguley

Vascular Disruptive Agents in Combination with Radiotherapy .......... 231
Henry C. Mandeville and Peter J. Hoskin

Index ................................................................................................................. 251
Vascular Disruptive Agents for the Treatment of Cancer
Meyer, T. (Ed.)
2010, IX, 256 p., Hardcover
ISBN: 978-1-4419-6608-7